3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
6
CNS
5
Other hematologic neoplasm
3
Lymphoid
3
Head & Neck
3
Endocrine
3
Tumor-Agnostic
2
Sarcoma
2
Genitourinary
2
Dermatologic
2
Other solid neoplasm
1
NET
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
lutetium Lu 177 dotatate
28
Magnetic Resonance Spectroscopy
15
Everolimus
10
pembrolizumab
9
Specimen Handling
9
cabozantinib
7
Nivolumab
7
Lutetium-177
6
surufatinib
5
lenvatinib
5
Octreotide
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
lanreotide
4
gallium Ga 68 dotatate
4
amino-acid, glucose, and electrolyte solution
4
X-Rays
4
Lutetium
4
Ipilimumab
4
Injections
4
Fluorodeoxyglucose F18
4
Capecitabine
4
olaparib
3
copper dotatate CU-64
3
atezolizumab
3
Temozolomide
3
Cyclophosphamide
3
Carboplatin
3
pasireotide
2
fludarabine phosphate
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
entrectinib
×
NET
×
1 year
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA